Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Freeman

Poquoson, VA Medical Doctor

NPI 1194973867 CMS profile 1386061

110 Laydon Way, Poquoson, VA 23662

Open in the dashboard

General payments

$4,789

55 records reported · program years 2019–2025

Research payments

$207,124

Paid to them · 116 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$21,334,158 paid to institutions, not to them · program years 2019–2025

Through program year 2025, George Freeman of Poquoson, VA is reported in the CMS Open Payments database as having received $4,789 across 55 general payments and $207,124 in research payments paid to them. Separately, studies naming them as principal investigator received $21,334,158 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,284 30
2024 General $35 1
2024 Research $840 1
2023 General $1,246 11
2023 Research $2,898 4
2022 General $70 2
2022 Research $541 2
2020 General $1,154 11
2020 Research $149,755 46
2019 Research $53,091 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Freeman
  • Virginia median
  • Middle half of Virginia
  • National median

In program year 2025, general payments to George Freeman were reported at $2,284. Among 24,845 Virginia profiles paid that year, the median was $179 and the middle half received between $56 and $613.

Show as a table
Year George Freeman Virginia median Middle half National median
2019 $0 $162 $50–$582 $163
2020 $1,154 $111 $36–$367 $114
2021 $0 $125 $37–$450 $132
2022 $70 $149 $45–$527 $149
2023 $1,246 $161 $50–$554 $160
2024 $35 $171 $55–$585 $164
2025 $2,284 $179 $56–$613 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,538 26 payments
  2. Eli Lilly and Company $2,219 28 payments
  3. Novo Nordisk Inc $32 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,993 37 payments
  2. Food and Beverage $727 16 payments
  3. Education $68 2 payments
Products named General payments · program years 2019–2025
  1. GARDASIL 9 $1,154 11 payments
  2. CAPVAXIVE $70 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Ichnos Sciences Inc. $143,266 44 payments
  2. Glenmark Pharmaceuticals Inc. $42,754 62 payments
  3. Eli Lilly and Company $13,312 8 payments
  4. GlaxoSmithKline, LLC. $5,793 1 payment
  5. Pfizer Inc. $2,000 1 payment

Records

171 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record